Caricamento...
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV‑1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation
We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1(HXB2), with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, a...
Salvato in:
| Pubblicato in: | J Med Chem |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7703574/ https://ncbi.nlm.nih.gov/pubmed/32031803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.9b02149 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|